Platelet inhibition beyond conventional antiplatelet agents: Expanding role of angiotensin receptor blockers, statins and selective serotonin reuptake inhibitors

International Journal of Clinical Practice

Volumn 60, Issue 8, 2006, Pages 993-1002

  Malinin, A I ^a   Ong, S ^a   Makarov, L M ^a   Petukhova, E Y ^a   Serebruany, V L ^a  

^a Osler Medical Center   (United States)

Author keywords

Angiotensin receptor blockers; Antiplatelet agents; Clinical trials; Platelets; Selective serotonin reuptake inhibitors; Statins

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; CANDESARTAN; CANGRELOR; CILOSTAZOL; CLOPIDOGREL; DIPYRIDAMOLE; FIBRINOGEN RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; LOSARTAN; PADGEM PROTEIN; PAROXETINE; PLACEBO; PRASUGREL; PROTEINASE ACTIVATED RECEPTOR 1; PYRIDINE DERIVATIVE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; STREPTOKINASE; THROMBIN RECEPTOR; THROMBOXANE RECEPTOR; UNINDEXED DRUG; VALSARTAN; VITRONECTIN RECEPTOR;

ANTICOAGULATION; ATHEROSCLEROSIS; BLEEDING DISORDER; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG BINDING SITE; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG RECEPTOR BINDING; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR DEPRESSION; NONHUMAN; PRIMARY PREVENTION; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; REVIEW; SECONDARY PREVENTION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT OUTCOME; VASCULAR DISEASE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; CARDIOVASCULAR DISEASES; DEPRESSIVE DISORDER; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PLATELET AGGREGATION INHIBITORS; SEROTONIN UPTAKE INHIBITORS;

EID: 33746218509     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2006.01063.x     Document Type: Review

References (130)

1. Heart Disease and Stroke Statistics -2006 Update. A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006; 113: E85.
2. Rogers WJ, Canto JG, Lambrew CT et al. Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the US from 1990 through 1999: The National Registry of Myocardial Infarction 1, 2 and 3. J Am Coll Cardiol 2000; 36: 2056-63.
3. Muntner P, Garrett E, Klag MJ, Coresh J. Trends in stroke prevalence between 1973 and 1991 in the US population 25 to 74 years of age. Stroke 2002; 33: 1209-13.
4. Popma JJ, Berger P, Ohman EM et al. Antithrombotic therapy during percutaneous coronary intervention: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 576S-99S.
5. Smith SC Jr, Feldman TE, Hirshfeld JW Jr et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol 2006; 47: 1-121.
6. Antman EM, Anbe DT, Armstrong PW et al. ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. J Am Coll Cardiol 2004; 44: 671-719.
7. Gibbons RJ, Abrams J, Chatterjee K et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina -summary article: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). J Am Coll Cardiol 2003; 41: 159-68.
8. Wiviott SD, Antman EM, Winters KJ et al. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: Results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation 2005; 111: 3366-73.
9. Husted S, Emanuelsson H, Heptinstall S et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: A double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006; 27: 1038-47.
10. Greenbaum AB, Grines CL, Bittle JA et al. Initial experience with the intravenous platelet P2Y12 receptor antagonist in patients undergoing percutaneous coronary intervention: Results from a 2-part, phase II, muticenter randomized, placebo-, and active control trial. Am Heart J 2006; 151: 689e1-10.
11. Chen ZM, Jiang LX, Chen YP et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: Randomised placebo-controlled trial. Lancet 2005; 366: 1607-21.
12. Bhatt DL, Fox KA, Hacke W et al. A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Heart J 2005; 150: 401.
13. Diener HC, Bogousslavsky J, Brass LM et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): Randomised, double-blind, placebo-controlled trial. Lancet 2004; 364: 331-7.
14. Peters RJ, Mehta SR, Fox KA et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: Observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 2003; 108: 1682-87.
15. Serebruany VL. Mortality benefit of no-load clopidogrel in COMMIT: Not a surprise. J Cardiovasc Pharm Therap 2006; 11: 99-100.
16. Hennekens CH. Increasing burden of cardiovascular disease: Current knowledge and future directions for research on risk factors. Circulation 1998; 97: 1095-102.
17. Ezzati M. How can cross-country research on health risks strengthen interventions? Lessons from INTERHEART. Lancet 2004; 364: 912-4.
18. Dahlof B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomized trial against atenolol. Lancet 2002; 359: 995-1003.
19. Lithell H, Hansson L, Skoog I et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): Principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21: 875-86.
20. Val-HeFT (Valsartan Heart Failure Trial): Cohn JN, Tognoni G. A randomized trial of the angiotensin receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667-75.
21. Yusuf S, Pfeffer MA, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved Trial. Lancet 2003; 362: 777-781.
22. Parving HH, Lehnert H, Brochner-Mortensen J et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-8.
23. Brenner BM, Cooper ME, Zeeuw Dd D et al. The losartan renal protection study-rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan). J Renin Angiotens Aldost Syst 2000; 1: 328-35.
24. Nadar S, Lip GY. The prothrombotic state in hypertension and the effects of antihypertensive treatment. Curr Pharm Des 2003; 9: 1715-32.
25. Siebers MJ, Goodfriend TL. Platelet angiotensin receptors in young and old humans. J Gerontol 1986; 41: 574-78.
26. Pawlak M, Macdonald G. Platelet angiotensin II receptors in pregnancy. Clin Sci (Lond) 1992; 83: 737.
27. Graves SW, Moore TJ, Seely EW. Increased platelet angiotensin II receptor number in pregnancy-induced hypertension. Hypertension 1992; 20: 627-32.
28. Baker PN, Broughton Pipkin F, Symonds EM. Platelet angiotensin II binding sites in hypertension in pregnancy. Lancet 1989; 2: 1151.
29. Suzuki H, Shibata H, Murakami M et al. Modulation of angiotensin II type 1 receptor mRNA expression in human blood cells: Comparison of platelets and mononuclear leucocytes. Endocr J 1995; 42: 15-22.
30. Shibata H, Suzuki H, Murakami M et al. Angiotensin II type 1 receptor messenger RNA levels in human blood cells of patients with primary and secondary hypertension: Reference to renin profile. J Hypertens 1994; 12: 1275-84.
31. 2+ concentrations in essential hypertension. Hypertension 1993; 22: 853-62.
32. Ferri C, De Angelis C, Del Porto MA et al. Blood platelets and angiotensin II: Angiotensin II release after platelet aggregation. J Hypertens 1988; 6: S69-71.
33. Larsson PT, Schwieler JH, Wallen NH. Platelet activation during angiotensin II infusion in healthy volunteers. Blood Coagul Fibrinolysis 2000; 11: 61-9.
34. Liu EC, Hedberg A, Goldenberg HJ et al. DuP 753, the selective angiotensin II receptor blocker, is a competitive antagonist to human platelet thromboxane A2/prostaglandin H2 (TP) receptors. Prostaglandins 1992; 44: 89-99.
35. Guerra-Cuesta JI, Monton M, Rodriguez-Feo JA et al. Effect of losartan on human platelet activation. J Hypertens 1999; 17: 447-52.
36. Criscione L, de Gasparo M, Buhlmayer P et al. Pharmacological profile of valsartan: A potent, orally active, nonpeptide antagonist of the angiotensin II AT 1 -receptor subtype. Br J Pharmacol 1993; 110: 761-71.
37. Serebruany VL, Malinin AI, Lowry DR et al. Platelet inhibition by valsartan and valeryl 4-hydroxy valsartan: A possible missing link to explain benefits of angiotensin II receptor blockers in patients after acute vascular events. J Cardiovasc Pharm 2004; 43: 677-84.
38. Kalinowski L, Matys T, Chabielska E et al. Angiotensin II AT1 receptor antagonists inhibit platelet adhesion and aggregation by nitric oxide release. Hypertension 2002; 40: 521-7.
39. Serebruany VL, Pokov AN, Malinin AI et al. Valsartan inhibits platelet activity at different doses in mild to moderate hypertensives: Valsartan inhibits platelets (VIP) trial. Am Heart J 2006; 151: 92-9.
40. Jimenez AM, Monton M, Garcia R et al. Inhibition of platelet activation in stroke-prone spontaneously hypertensive rats: Comparison of losartan, candesartan, and valsartan. J Cardiovasc Pharmacol 2001; 37: 406-12.
41. Li P, Fukuhara M, Diz DI et al. Novel angiotensin II AT(1) receptor antagonist irbesartan prevents thromboxane A(2)-induced vasoconstriction in canine coronary arteries and human platelet aggregation. J Pharmacol Exp Therap 2000; 292: 238-46.
42. Lopez-Farre A, Sanchez Miguel de L et al. Angiotensin II AT(1) receptor antagonists and platelet activation. Nephrol Dial Transplant 2001; 16: S45-9.
43. Monton M, Jimenez A, Nunez A et al. Comparative effects of angiotensin II AT-1-type receptor antagonists in vitro on human platelet activation. J Cardiovasc Pharmacol 2000; 35: 906-13.
44. Radomski MW, Moncada S. Regulation of vascular homeostasis by nitric oxide. Thromb Haemost 1993; 70: 36-41.
45. Riddell DR, Owen JS. Nitric oxide and platelet aggregation. Vitam Horm 1999; 57: 25-48.
46. Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 1997; 278: 313-21.
47. Rutishauser J. The role of statins in clinical medicine -LDL - cholesterol lowering and beyond. Swiss Med Wkly 2006; 136: 41-9.
48. Serruys PW, de Feyter P, Macaya C et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: A randomized controlled trial. JAMA 2002; 287: 3215-22.
49. Futterman LG, Lemberg L. Statin pleiotropy: Fact or fiction ? Am J Crit Care 2004; 13: 244-9.
50. Halcox JP, Deanfield JE. Beyond the laboratory: Clinical implications for statin pleiotropy. Circulation 2004; 109: II42-8.
51. Liao JK. Clinical implications for statin pleiotropy. Curr Opin Lipidol 2005; 16: 624-9.
52. Epstein M, Campese VM. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors on renal function. Am J Kidney Dis 2005; 45: 2-14.
53. McCarey DW, Sattar N, McInnes IB. Do the pleiotropic effects of statins in the vasculature predict a role in inflammatory diseases ? Arthritis Res Ther 2005; 7: 55-61.
54. Sotiriou CG, Cheng JW. Beneficial effects of statins in coronary artery disease-beyond lowering cholesterol. Ann Pharmacother 2000; 34: 1432-9.
55. Schafer K, Kaiser K, Konstantinides S. Rosuvastatin exerts favourable effects on thrombosis and neointimal growth in a mouse model of endothelial injury. Thromb Haemost 2005; 93: 145-2.
56. Undas A, Brozek J, Musial J. Anti-inflammatory and antithrombotic effects of statins in the management of coronary artery disease. Clin Lab 2002; 48: 287-96.
57. Serebruany VL, Midei MG, Malinin AI et al. Absence of interaction between atorvastatin or other statins and clopidogrel: Results from the INTERACTION study. Arch Intern Med 2004; 164: 2051-7.
58. Serebruany VL, Miller M, Pokov AN et al. Effect of Statins on Platelet PAR-1 Thrombin Receptor in Patients With the Metabolic Syndrome (From the PAR-1 Inhibition by Statins [PARIS] Study). Am J Cardiol 2006; 97: 1332-6.
59. Sanguigni V, Pignatelli P, Caccese D et al. Increased superoxide anion production by platelets in hypercholesterolemic patients. Thromb Haemost 2002; 87: 796-801.
60. Laufs U, Gertz K, Huang P et al. Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. Stroke 2000; 31: 2442-9.
61. Tannous M, Cheung R, Vignini A, Mutus B. Atorvastatin increases ecNOS levels in human platelets of hyperlipidemic subjects. Thromb Haemost 1999; 82: 1390-4.
62. Puccetti L, Pasqui AL, Pastorelli M et al. Time-dependent effect of statins on platelet function in hypercholesterolaemia. Eur J Clin Invest 2002; 32: 901-8.
63. Mosheimer BA, Kaneider NC, Feistritzer C et al. CD40-ligand-dependent induction of COX-2 gene expression in endothelial cells by activated platelets: Inhibitory effects of atorvastatin. Blood Coagul Fibrinolysis 2005; 16: 105-10.
64. De Cristofaro R, De Candia E. Thrombin domains: Structure, function and interaction with platelet receptors. J Thromb Thrombolysis 2003; 15: 151-63.
65. Patterson C, Stouffer GA, Madamanchi N, Runge MS. New tricks for old dogs: Nonthrombotic effects of thrombin in vessel wall biology. Circ Res 2001; 88: 987-97.
66. Cupit LD, Schmidt VA, Bahou WF. Proteolytically activated receptor-3. A member of an emerging gene family of protease receptors expressed on vascular endothelial cells and platelets. Trends CardioVasc Med 1999; 9: 42-8.
67. Vu TK, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991; 64: 1057-68.
68. Kahn ML, Nakanishi-Matsui M, Shapiro MJ et al. Protease activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest 1999; 103: 879-87.
69. Phillips DR. Thrombin interaction with human platelets. Potentiation of thrombin-induced aggregation and release by inactivated thrombin. Thromb Diath Haemorrh 1974; 32: 207-15.
70. Henriksen RA, Samokhin GP, Tracy PB. Thrombin-induced thromboxane synthesis by human platelets. Properties of anion binding exosite I-independent receptor. Arterioscler Thromb Vasc Biol 1997; 17: 3519-26.
71. Weksler BB, Ley CW, Jaffe EA. Stimulation of endothelial cell prostacyclin production by thrombin, trypsin, and the ionophore A23187. J Clin Invest 1978; 62: 923-30.
72. Sugama Y, Tiruppathi C, offakidevi K et al. Thrombin-induced expression of endothelial P-selectin and intercellular adhesion molecule-1: A mechanism for stabilizing neutrophil adhesion. J Cell Biol 1992; 119: 935-44.
73. Major CD, Santulli RJ, Derian CK, Andrade-Gordon P. Extracellular mediators in atherosclerosis and thrombosis: Lessons from thrombin receptor knockout mice. Arterioscler Thromb Vasc Biol 2003; 23: 931-9.
74. Flynn AN, Buret AG. (PAR-1) and cell apoptosis. Apoptosis 1 2004; 9: 729-37.
75. Sabri A, Guo J, Elouardighi H et al. Mechanisms of protease-activated receptor-4 actions in cardiomyocytes. Role of Src tyrosine kinase. J Biol Chem 2003; 278: 11714-20.
76. Mandal SK, Rao LV, Tran TT, Pendurthi UR. A novel mechanism of plasmin-induced mitogenesis in fibroblasts. J Thromb Haemost 2005; 3: 163-9.
77. Jurk K, Jahn UR, Van Aken H et al. Platelets in patients with acute ischemic stroke are exhausted and refractory to thrombin, due to cleavage of the seven-transmembrane thrombin receptor (PAR-1). Thromb Haemost 2004; 91: 334-44.
78. Fenton JW II, Jeske WP, Catalfamo JL et al. Statin drugs and dietary isoprenoids downregulate protein prenylation in signal transduction and are antithrombotic and prothrombolytic agents. Biochemistry (Mosc). 2002; 67: 85-91.
79. Puccetti L, Bruni F, Bova G et al. Effect of diet and treatment with statins on platelet-dependent thrombin generation in hypercholesterolemic subjects. Nutr Metab Cardiovasc Dis 2001; 11: 378-87.
80. Barth J, Schumacher M, Herrmann-Lingen C. Depression as a risk factor for mortality in patients with coronary heart disease: A meta-analysis. Psychosom Med 2004; 66: 802-13.
81. Frasure-Smith N, Lesperance F, Talajic M. Depression following myocardial infarction - impact on 6 -month survival. JAMA 1993; 270: 1819-25.
82. Carney RM, Blumenthal JA, Freedland KE et al. Depression and late mortality after myocardial infarction in the Enhancing Recovery in Coronary Heart Disease (ENRICHD) study. Psychosom Med 2004; 66: 466-74.
83. Lett HS, Blumenthal JA, Babyak MA et al. Depression as a risk factor for coronary artery disease: Evidence, mechanisms, and treatment. Psychosom Med 2004; 66: 305-15.
84. Akhtar MS, Malik SB, Ahmed MM. Symptoms of depression and anxiety in post-myocardial infarction patients. Coll Physicians Surg Pak 2004; 14: 615-8.
85. Grace SL, Abbey SE, Irvine J et al. Prospective examination of anxiety persistence and its relationship to cardiac symptoms and recurrent cardiac events. Psychother Psychosom 2004; 73: 344-52.
86. Lane D, Carroll D, Ring C et al. The prevalence and persistence of depression and anxiety following myocardial infarction. Br J Health Psychol 2002; 7: 11-21.
87. Ahern DK, Gorkin L, Anderson JL et al. Biobehavioral variables and mortality or cardiac arrest in the Cardiac Arrhythmia Pilot Study (CAPS). Am J Cardiol 1990; 66: 59-62.
88. Frasure-Smith N, Lesperance F, Talajic M. Depression and 18-month prognosis after myocardial infarction. Circulation 1995; 91: 999-1005.
89. Vigo DE, Nicola Siri L, Ladron De Guevara MS et al. Relation of depression to heart rate nonlinear dynamics in patients >or=60years of age with recent unstable angina pectoris or acute myocardial infarction. Am J Cardiol 2004; 93: 756-60.
90. Glassman AH, O'Connor CM, Califf RM et al. Sertraline Antidepressant Heart Attack Randomized Trial (SADHART) Group. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 2002; 288: 701-9.
91. Serebruany VL, Glassman AH, Malinin AI et al. Sertraline AntiDepressant Heart Attack Randomized Trial Study Group: Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: The Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation 2003; 108: 939-44.
92. Musselman DL, Tomer A, Manatunga AC et al. Exaggerated platelet reactivity in major depression. Am J Psychiat 1996; 153: 1313-17.
93. Mc Adam C, Colaham FJ, Brophy J, Leonard BE. Alterations of plasma factor of platelet aggregation and 5-HT untake in depression. Biol Psych 1992; 32: 296-8.
94. Serebruany VL, Gurbel PA, O'Connor CM. Platelet inhibition by sertraline and N -desmethylsertraline: A possible missing link between depression, coronary events, and mortality benefits of selective serotonin reuptake inhibitors. Pharm Res 2001; 43: 453-62.
95. Serebruany VL, O'Connor CM, Gurbel PA. Effect of selective serotonin reuptake inhibitors on platelets in patients with coronary artery disease. Am J Cardiol 2001; 87: 1398-400.
96. Musselman DL, Marzec UM, Manatunga A et al. Platelet reactivity in depressed patients treated with paroxetine. Arch Gen Psych 2000; 57: 875-82.
97. Atar D, Malinin A, Takserman A et al. Escitalopram, but not its major metabolites, exhibits antiplatelet activity in humans. J Clin Psychopharmacol 2006; 26: 172-7.
98. Serebruany VL, Gurbel PA, Shustov AR et al. Heterogeneity of platelet aggregation and major surface receptor expression in patients presenting with acute myocardial infarction. Am Heart J 1998; 136: 398-405.
99. Gurbel PA, Serebruany VL, Shustov AR et al. Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. The GUSTO III Platelet Study. J Am Coll Cardiol 1998; 31: 1466-1473.
100. Briley MS, Raisman R, Sechter D et al. (H) Imipramine binding in human platelets: A new biochemical parameters in depression. Neuropharmacology 1980; 19: 1209-10.
101. Hrdina PD, Bakish D, Ravindran A et al. Platelet serotonergic indices in major depression: Up-regulation of 5-HT2A receptors unchanged by antidepressant treatment. Psychiatr Res 1997; 66: 73-85.
102. Dwivedi Y, Janicak PG, Pandey GN. Elevated [3H]inositol 1,4,5-trisphosphate binding sites and expressed inositol 1,4,5-trisphosphate receptor protein level in platelets of depressed patients. Psychopharmacology 1998; 138: 47-54.
103. Schleifer SJ, Macari-Hinson MM, Coyle DA et al. Platelet monoamine oxidase activity in elderly depressed out patients. Biol Psychiatr 1986; 21: 1360-4.
104. Wahlund B, Saaf J, Wetterberg L. Classification of patients with affective disorders using platelet monoamine oxidase activity, serum melatonin and post-dexamethasone cortisol. Acta Psychiatr Scand 1995; 91: 313-21.
105. Reichborn-Kjennerud T, Lingjaerde O, Oreland L. Platelet monoamine oxidase activity in patients with winter seasonal affective disorder. Psychiatr Res 1996; 63: 273-80.
106. Laghrissi-Thode F, Wagner WR, Pollock BG et al. Elevated platelet factor 4 and beta-thromboglobulin plasma levels in depressed patients with ischemic heart disease. Biol Psychiatr 1997; 42: 290-5.
107. Musselman DL, Marzec U, Davidoff M et al. Platelet activation and secretion in patients with major depression, thoracic aortic atherosclerosis, or renal dialysis treatment. Depress Anxiety 2002; 15: 91-101.
108. Doogan DP, Caillard V. Sertraline: A new antidepressant. J Clin Psychiatr 1988; 49.
109. Tuomisto J, Tukiainen E. Decreased uptake of 5-hydroxytryptamine in blood platelets from depressed patients. Nature 1976; 262: 596.
110. Coopen A, Swade C, Wood K. Platelet 5HT accumulation in depressive illness. Clin Chim Acta 1978; 87: 165-8.
111. Biegon A, Weizman A, Karp L et al. Serotonin 5-HT2 receptor binding on blood platelets - a peripheral marker for depression. Life Sci 1987; 40: 2485-92.
112. Sheline YI, Bardgett ME, Jackson JL et al. Platelet serotonin markers and depressive symptomatology. Biol Psychiatr 1995; 37: 442-7.
113. Delisi SM, Konopka LM, O'Connor FL, Crayton JW. Platelet cytosolic calcium responses to serotonin in depressed patients and controls: relationship to symptomatology and medication. Biol Psychiatr 1998; 43: 327-34.
114. Konopka LM, Cooper R, Crayton JW. Serotonin-induced increases in platelet cytosolic calcium concentration in depressed, schizophrenic, and substance abuse patients. Biol Psychiatr 1996; 39: 708-13.
115. Menninger JA, Tabakoff B. Forskolin-stimulated platelet adenylyl cyclase activity is lower in persons with major depression. Biol Psychiatr 1997; 42: 30-38.
116. Garcia-Sevilla JA, Escriba PV, Busquets X et al. Platelet imidazoline receptors and regulatory G proteins in patients with major depression. Neuroreport 1996; 8: 169-172.
117. Karege F, Bovier P, Stepanian R, Malafosse A. The effect of clinical outcome on platelet G proteins of major depressed patients. Eur Neuropsychopharmacol 1998; 8: 89-94.
118. Nugent DF, Dinan TG, Leonard BE. Alteration by a plasma factor(s) of platelet aggregation in unmedicated unipolar depressed patients. J Affect Disord 1994; 31: 61-6.
119. Nugent DF, Dinan TG, Leonard BE. Further characterization of the inhibition of platelet aggregation by a plasma factor(s) in unmedicated unipolar depressed patients. J Affect Disord 1995; 33: 227-31.
120. Maes M, Van der Planken M, Van Gastel A, Desnyder R. Blood coagulation and platelet aggregation in major depression. J Affect Disord 1996; 40: 35-40.
121. Karege F, Bovier P, Hilleret H et al. Adrenaline-induced platelet aggregation in depressed patients and control subjects. Neuropsychobiology 1993; 27: 21-5.
122. Butler J, Leonard BE. The platelet serotonergic system in depression and following sertraline treatment. Int Clin Psychopharmacol 1988; 3: 343-7.
123. Alderman CP, Seshadri P, Ben-Tovim DI. Effects of serotonin reuptake inhibitors on hemostasis. Ann Pharmacother 1996; 30: 1232-4.
124. Alderman CP, Moritz CK, Ben-Tovim DI. Abnormal platelet aggregation associated with fluoxetine therapy. Ann Pharmacother 1992; 26: 1517-1519.
125. Pai VB, Kelly MW. Bruising associated with the use of fluoxetine. Ann Pharmacother 1996; 30: 786-8.
126. Skop BP, Brown TM. Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors. Psychosomatics 1996; 37: 12-16.
127. Willerson JT, Eidt JF, McNatt J et al. Role of thromboxane and serotonin as mediators in the development of spontaneous alterations in coronary blood flow and neointimal proliferation in canine models with chronic coronary artery stenosis and endothelial injury. J Am Coll Cardiol 1991; 17 (Suppl. B): 101B-10B.
128. Serebruany VL, Gurbel PA, O'Connor CM. Platelet inhibition by sertraline and N-desmethylsertraline: A possible missing link between depression, coronary events, and mortality benefits of selective serotonin reuptake inhibitors. Pharmacol Res 2001; 43: 453-62.
129. von Moltke LL, Greenblatt DJ, Giancarlo GM et al. Escitalopram (S-citalopram) and its metabolites in vitro: Cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. Drug Metab Dispos 2001; 29: 1102-9.
130. Pfisterer ME, Kaiser CA, Bader F et al. Late clinical events related to late stent thrombosis after stopping clopidogrel: Prospective randomized comparison between drug-eluting versus bare-metal stenting. JACC 2006; 47 (Suppl.): A422-11.